Clinical Trials Logo

Esophageal Neoplasms clinical trials

View clinical trials related to Esophageal Neoplasms.

Filter by:

NCT ID: NCT03799380 Completed - Esophageal Cancer Clinical Trials

DRIHNC - Dehydration Reduction in Head & Neck Cancer

Start date: November 5, 2019
Phase: N/A
Study type: Interventional

The purpose of this study is to decrease the rate of visits to the Emergency Department (ED) and Acute Care Clinics (ACC) for dehydration for head & neck (H&N) and esophageal cancer patients that are given Gatorade while receiving radiation therapy with or without chemotherapy.

NCT ID: NCT03798951 Terminated - Clinical trials for Esophageal Cancer Surgery

Prehabilitation in Esophageal Surgery (PRESS)

PRESS
Start date: June 5, 2019
Phase: N/A
Study type: Interventional

Despite important clinical improvements, esophageal cancer surgery is still associated to a high rate of postoperative complications. Recent ERAS (Enhanced Recovery After Surgery) Society guidelines underline the possible role of prehabilitations' programs in reducing postoperative morbidity. In this trial, 200 patients, scheduled for esophageal cancer resection, will be randomly assigned to two groups (100 patients for each group). In both groups, patients will perform a basal evaluation with a physiotherapist, a nutritionist and a psychologist. In the treatment group, each patient will receive a tailored prehabilitative program and, during the 4 weeks before surgery, will be monitored constantly by each single specialist. A preoperative revaluation (the day before surgery) and follow up visits at 3 and 6 months will be performed for all patients. The incidence of postoperative complications, the length of hospital stay, and the reach of discharge criteria will be registered.

NCT ID: NCT03797625 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Start date: May 4, 2017
Phase: Phase 2
Study type: Interventional

The aim of this study is to explore whether endostar combined with IP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens

NCT ID: NCT03791905 Recruiting - Clinical trials for Squamous Cell Carcinoma

PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma

Start date: January 15, 2019
Phase: Phase 2
Study type: Interventional

Since multiple studies have demonstrated that PET can identify responders and non-responders to induction chemotherapy, using FDG-PET imaging to guide treatment decisions has prompted interest in clinical practice. The aim of this study was to evaluate whether changing chemotherapy regimen during radiation based on PET response to induction chemotherapy can improve clinical complete response (cCR) in patients with unresectable esophageal squamous cell carcinoma (ESCC).

NCT ID: NCT03790553 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma

Start date: October 15, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.

NCT ID: NCT03787537 Completed - Colorectal Cancer Clinical Trials

Nutritional Status and Nutrient Supply in Hospitalised Surgical Patients

Start date: August 1, 2017
Phase:
Study type: Observational

Prospective single arm, single center observational study to assess the nutritional status and the nutrient supply during hospitalization for elective gastrointestinal surgery.

NCT ID: NCT03787251 Withdrawn - Clinical trials for Esophageal Neoplasms

A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib

Start date: January 1, 2019
Phase: Phase 2
Study type: Interventional

A study of second-line treatment of postoperative recurrence and metastasis of esophageal squamous cell carcinoma after chemotherapy with apatinib mesylate

NCT ID: NCT03785496 Active, not recruiting - Clinical trials for Histologically Confirmed Unresectable or Metastatic Squamous Cell Carcinoma of the Esophagus Who Failed on Standard Treatment

Study to Evaluate Efficacy of PDR001 in Patients With Squamous Cell Carcinoma of the Esophagus

Start date: February 18, 2020
Phase: Phase 2
Study type: Interventional

Single arm phase II PDR001( 300mg, IV) will be treated every 3 weeks

NCT ID: NCT03784326 Recruiting - Clinical trials for Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Start date: February 19, 2019
Phase: Phase 2
Study type: Interventional

To learn if atezolizumab in combination with oxaliplatin and 5-fluorouracil (5-FU), when given before surgery, can help to control esophageal and/or gastroesophageal cancer. To learn if adding tiragolumab to the above drug combination can help to control the disease.

NCT ID: NCT03783936 Completed - Clinical trials for Gastric Adenocarcinoma

Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas

Start date: January 24, 2019
Phase: Phase 2
Study type: Interventional

The initial intent of the study was to be a multi-center single-arm open-label Simon's two-stage Phase II clinical trial of first-line mFOLFOX6 + trastuzumab + avelumab in metastatic HER2-amplified gastric and esophageal adenocarcinomas. Accrual will halt after completion of Stage I (enrollment of 18 patients). This decision is not due to safety issues. Subjects currently on treatment will continue until criteria as defined in the protocol is met.